Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2020

View Archived Issues

Immunocytokines jumpstart anti-glioblastoma immunity

Structural insights into small-molecule GLP-1 agonists

FDA clears IND for phase I/IIa study of AstroStem-V to treat COVID-19 patients with pneumonia

Enrollment begins in phase II ASUNCTIS study of asunercept in patients with COVID-19

NIH launches ACTIV-5/BET trial to identify new promising COVID-19 treatments

New osteoporosis treatment target, inhibitor identified

Universita degli Studi di Milano and collaborators describe inhibitors of miR-129

Cyclerion provides updates on their development of olinciguat and IW-6463

New MAP3K5 inhibitors identified at Enanta Pharmaceuticals

California Institute of Technology, 1200 Pharma and UC Oakland disclose PRMT5 inhibitors

Columbia University, Forkhead BioTherapeutics synthesize new FOXO1 inhibitors

New galectin-3 inhibitors discovered at Bristol Myers Squibb

Novan presents positive in vitro data for its NITRICIL platform technology against SARS-CoV-2

FDA grants approval for expanded use of Wakix for cataplexy in adult patients with narcolepsy

Sorrento cleared for phase II trial in Brazil of abivertinib for mild, moderate and severe COVID-19

Arvinas announces new preclinical programs

Janssen begins phase III evaluation of seltorexant as adjunctive therapy for MDD with insomnia

Astellas describes discovery of novel PET probe for fatty acid oxidation

First subject dosed in phase I study of AZP-3601

FDA clears IND for 177Lu-omburtamab-DTPA

KKC-080106 shows promising neuroprotective activity in preclinical models

Ankasa begins phase Ib/IIa evaluation of ART352-L in posterolateral spinal fusion

Roche begins phase III study of GDC-9545 with palbociclib in advanced breast cancer

FDA approves Inmazeb for Zaire ebolavirus

Vertex discontinues development of VX-814 for alpha-1 antitrypsin deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...